According to Merck KGaA's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.2273. At the end of 2022 the company had a P/E ratio of 23.7.
Year | P/E ratio | Change |
---|---|---|
2022 | 23.7 | -26.67% |
2021 | 32.3 | 5.14% |
2020 | 30.7 | -11.67% |
2019 | 34.8 | 198.53% |
2018 | 11.6 | -22.27% |
2017 | 15.0 | -43.33% |
2016 | 26.4 | -24.14% |
2015 | 34.9 | 18.22% |
2014 | 29.5 | 25.39% |
2013 | 23.5 | -39.78% |
2012 | 39.0 | 41.9% |
2011 | 27.5 | 33.76% |
2010 | 20.6 | -46.97% |
2009 | 38.8 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.